Key points are not available for this paper at this time.
Introduction Most patients with breast cancer have early-stage hormone receptor(HR)-positive, human epidermal growth factor receptor-2 (HER2)-negativedisease. Even though the prognosis for most of these patients is good, there isa need to identify patients at risk for poor outcomes and to develop strategiesto mitigate this risk.
Schlam et al. (2024) studied this question.